The inhibitory effect in experimental autoimmune encephalomyelitis by the immunomodulatory drug Linomide (PNU-212616) is not mediated via release of endogenous glucocorticoids

Autoimmunity

Volumn 28, Issue 4, 1998, Pages 235-241

  Pekarski, Olga ^a   Björk, Jakob ^a   Hedlund, Gunnar ^a,b   Andersson, Gunnar ^a,b  

^a Pharmacia & Upjohn AB   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Autoimmunity; Corticosterone; EAE; Linomide; SJL N mice

Indexed keywords

CORTICOSTERONE; GLUCOCORTICOID; IMMUNOMODULATING AGENT; PNU 212616; ROQUINIMEX; UNCLASSIFIED DRUG;

ADRENALECTOMY; ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DRUG MECHANISM; FEMALE; MOUSE; NONHUMAN;

EID: 0032446574     PISSN: 08916934     EISSN: None     Source Type: Journal    
DOI: 10.3109/08916939808995371     Document Type: Article

References (20)

1. Swanborg, R.H. Experimental autoimmune encephalomyelitis in rodents as a model for human demyelinating disease. Clin. Immunol. Immunopathol. 1995; 77: 4-13.
2. Karussis, D.M., Lehmann, D., Slavin, S., Vourka-Karussis, U., Mizrachi-Koll, R., Ovadia, H. et al. Inhibition of acute, experimental autoimmune encephalomyelitis by the synthetic immunomodulator Linomide. Ann. Neurology 1993; 34: 654-60.
3. Karussis, D.M., Lehmann, D., Slavin, S., Vourka-Karussis, U., Mizrachi-Koll, R., Ovadia, H. et al. Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator Linomide (quinoline-3-carboxamide). Proc. Natl. Acad. Sci. USA 1993; 90: 6400-04.
4. Tarkowski, A., Gunnarsson, K. and Stålhandske, T. Effects of LS-2616 administration upon the autoimmune disease of (NZBxNZW) F1 hybrid mice. Immunology 1986; 59: 589-94.
5. Björk, J. and Kleinau, S. Paradoxical effects of LS-2616 (Linomide) treatment in the type II collagen arthritis model in mice. Agents and Actions 1989; 27: 319-21.
6. Gross, D.J., Sidi, H., Weiss, L., Kalland, T., Rosenmann, E. and Slavin, S. Prevention of diabetes mellitus in non-obese diabetic mice by Linomide, a novel immunomodulating drug. Diabetologica 1994; 37: 1195-1201.
7. Karussis, D.M., Lehmann, D., Brenner, T., Wirguin, I., Mizrachi-Koll, R., Sicsic, C. et al. Immunomodulation of experimental autoimmune myasthenia gravis with Linomide. J. Neuroimmunol. 1994; 55: 187-93.
8. Christensen, U.B., Mauricio, D., Reimers, J.I., Andersen, H.U., Kalland, T., Nerup, J. and Mandrup-Poulsen, T. Linomide increases plasma corticosterone in normal rats, but does not prevent the inhibitory action of IL-1 on β-cells in vivo or ex vivo. Autoimmunity 1996; 23: 257-68.
9. MacPhee, I.A.M., Antoni, F.A. and Mason, D.W. Spontaneous recovery of rats from experimental allergic encephalomyelitis is dependent on regulation of the immune system by endogenous adrenal corticosteroids. J. Exp. Med. 1989; 169: 431-45.
10. Mason, D., MacPhee, I. and Antoni, F. The role of the neuroendocrine system in determining genetic susceptibility to experimental allergic encephalomyelitis in the rat. Immunology 1990; 70: 1-5.
11. Griffin, A.C., Lo, W.D., Wolny, A.C. and Whitacre, C.C. Suppression of experimental autoimmune encephalomyelitis by restrain stress: sex differences. J. Neuroimmunol. 1993; 44: 103-16.
12. Reder, A.T., Thapar, M. and Jensen, M.A. A reduction in serum glucocorticoids provokes experimental allergic encephalomyelitis: Implications for treatment of inflammatory brain disease. Neurolog. 1994; 44: 2289-94.
13. Purba, J.S., Raadsheer, F.C., Hofman, M.A., Ravid, R., Polman, C.H., Kamphorst, W. et al. Increased number of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of patients with multiple sclerosis. Neuroendocrinol. 1995; 62: 62-70.
14. Harbuz, M.S., Leonard, J.P., Lightman, S.L. and Cuzner, M.L. Changes in hypothalamic corticotrophin-releasing factor and anterior pituitary pro-opiomelanocortin mRNA during the course of experimental allergic encephalomyelitis. J. Neuroimmunol. 1993; 45: 127-32.
15. Besedovsky, H., del Rey, A., Sorkin, E. and Dinarello, C.A. Immunoregulatory feedback between Interleukin-1 and Glucocorticoid hormones. Science 1986; 233: 652-4.
16. Vukanovic, J., Hartley-Asp, B. and Isaacs, J.T. Inhibition of tumor angiogenesis and the therapeutic ability of Linomide against rat prostatic cancers. The Prostate 1995; 26: 235-46.
17. Kroemer, G. The pharmacology of T-cell apoptosis. In: Dixon F.J. (ed.) Advances in Immunology. Vol. 58 San Diego: Academic Press. 1995; 211-96.
18. Kalland, T., Alm, G. and Stålhandske, T. Augmentation of mouse natural killer cell activity by LS 2616, a new immunomodulator. J. Immunol. 1985; 134: 3956-61.
19. Slavin, S., Sidi, H., Weiss, L., Rosenman, E., Kalland, T. and Gross, D. Linomide, a new treatment for autoimmune diseases: The potential in Type 1 diabetes. Diabetes/ Metabolism Reviews 1993; 9: 311-25.
20. Gonzalo, J.A., González-Garcia, A., Kalland, T., Hedlund, G., Martínez-A, C. and Kroemer, G. Linomide, a novel immunomodulator that prevents death in four models of septic shock. Eur. J. Immunol. 1993; 23: 2372-74.